In Vivo Diagnosis Or In Vivo Testing Patents (Class 424/9.1)
  • Patent number: 11363997
    Abstract: A method, system, apparatus, and/or device that may include: a housing, a sensor interface, and a processing device. The housing may be shaped to be affixed to a body of a user and may include an inner cavity that houses electronic components and an impedance sensor. The impedance sensor may include a first contact terminal and a second contact terminal. The sensor interface may be configured to: generate an electric signal; receive the electric signal through a skin layer below a surface of the body of the user; and determine an impedance measurement between the first contact terminal and the second contact terminal based on the electric signal. The processing device may be configured to determine, based on the impedance measurement: a condition of a vascular system of the user; an amount of a constituent of the vascular system of the user; or a hydration condition of the user.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: June 21, 2022
    Inventors: David Miller, Jeffrey Lee, Devin Miller
  • Patent number: 11364305
    Abstract: Described herein are nanoparticle-based compositions, kits and methods and platforms for delivering one or more nucleic acids to a cell.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: June 21, 2022
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Paolo Serafini, Jennifer Vella, Vincenzo Bronte, Pirouz Daftarian, Angel Kaifer, Serena Zilio
  • Patent number: 11364279
    Abstract: A medicament for use in treating hypertension. The medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: June 21, 2022
    Assignee: SHANDONG ZHONGHAI PHARMACEUTICAL CO. LTD
    Inventors: Long Cheng, Baozhen Xu, Qian Cheng
  • Patent number: 11359016
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: June 14, 2022
    Assignee: ADAGENE INC.
    Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
  • Patent number: 11361867
    Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium are provided, including a method for presenting information for treating patients. The method comprises presenting, in a user interface, a pathway for use in treating a patient with a disease and including a combination of therapeutic and diagnostic pathway elements including an integration of diagnostic, radiation, chemotherapy, surgical and other elements. The method further comprises augmenting the pathway including providing controls for accessing additional information associated with a given pathway element, augmenting pathway elements to include indicators for pricing, efficacy and/or toxicity of a treatment associated with a given treatment element, and augmenting the pathway with a connection to another pathway including providing a link to another pathway at a point in a given pathway that provides information for a related pathway.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 14, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Alan F. List, Mark Gerard Schippits
  • Patent number: 11357735
    Abstract: The present invention relates to the localized delivery of nucleic acids to cells using polyelectrolyte assemblies in the form of particles that are prepared by layer-by-layer deposition of nucleic acid and specific polycation. It also relates to compositions comprising said particles and methods for the treatment of disorders or diseases by administration of such particles.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: June 14, 2022
    Inventors: Sabrina Belbekhouche, André Pawlak, Djillali Sahali, Benjamin Carbonnier
  • Patent number: 11357803
    Abstract: The present invention is directed to synbiotic compositions of probiotic strains and prebiotics, along with uses thereof for targeted human and animal applications, for example, in promoting health and well-being and/or treating therapeutic conditions. The present invention is also directed to methods of probiotic selection and detection of strains with the ability to produce neurochemicals in the gastrointestinal tract of a subject, providing a microbial endocrinology-based mechanism and approach for optimization of synbiotic delivery of a probiotic with a neurochemical precursor. Still further the present invention is directed to industrial applications for production of dopamine utilizing methods and media suitable for the same.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: June 14, 2022
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Mark Lyte, Daniel Nicholas Villageliu
  • Patent number: 11340225
    Abstract: The present disclosure provides methods of assaying for antibody-dependent cell-mediated phagocytosis (ADCP). In some embodiments, the methods include monomerizing and labeling a protein, contacting the protein with a protein-specific antibody to form an antibody-protein complex, contacting the antibody-protein complex with a phagocytic cell to permit phagocytosis, and assessing the amount of internalized fluorescence.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 24, 2022
    Assignee: Biogen International Neuroscience GmbH
    Inventors: Carl Co, Allyson Masci, Svetlana Bergelson
  • Patent number: 11339395
    Abstract: Provided herein are genetic circuits and cell state classifiers for detecting the microRNA profile of a cell. In some embodiments, the cell state classifiers described herein utilize an endoribonuclease and a self-amplifying RNA molecule for controlling the expression of an output molecule. In some embodiments, the cell state classifiers described herein are encoded on a single RNA transcript, which is then processed to produce individual genetic circuits that function independently. The genetic circuits and cell state classifiers described herein may be used in various applications (e.g., therapeutic or diagnostic applications).
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: May 24, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Ron Weiss, Kevin J. Lebo, Jin Huh
  • Patent number: 11332517
    Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: May 17, 2022
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Yee-Peng Chan, Christopher C. Broder
  • Patent number: 11332546
    Abstract: Certain embodiments provide isolated anti-MMP-14 antibodies or fragments thereof, isolated anti-MMP-12 antibodies or fragments thereof, isolated anti-BACE-1 antibodies or fragments thereof, isolated anti-Alp2 antibodies or fragments thereof, and isolated anti-cathepsin B antibodies or fragments thereof, as well as methods of use thereof.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: May 17, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Xin Ge, Kibaek Lee
  • Patent number: 11332773
    Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 17, 2022
    Assignee: KEIO UNIVERSITY
    Inventors: Shigeto Shimmura, Shin Hatou, Emi Inagaki, Kazuo Tsubota
  • Patent number: 11318100
    Abstract: Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: May 3, 2022
    Assignee: MAIA Pharmaceuticals, Inc.
    Inventor: Srikanth Sundaram
  • Patent number: 11318162
    Abstract: Provided is a method or the like for producing a composition exhibiting cytocidal activity. This method for producing a composition exhibiting cytocidal activity comprises: culturing malignant tumor-derived cells in a culture medium at least until the cell density reaches a level that does not pose a problem for transfer; replacing, after culturing, the culture medium with a physiological buffer salt solution; and recovering the physiological buffer salt solution after death of the malignant tumor-derived cells is observed morphologically in the physiological buffer salt solution.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 3, 2022
    Assignee: Medical Corporation Ichikawa Clinic
    Inventors: Tomoyuki Tajima, Yoshifusa Kondo
  • Patent number: 11318176
    Abstract: The present invention relates to a topical composition of facilitating wound healing and reducing scars, which includes an inactivated culture of Lactobacillus species as an effective ingredient and can significantly facilitate wound healing as well as reducing scars, thereby can be applied to a method of facilitating wound healing and reducing scars.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: May 3, 2022
    Assignee: GenMont Biotech Incorporation
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Wen-Wei Chang, Chia-Hsuan Chou
  • Patent number: 11306346
    Abstract: The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen. The present invention also provides a method for diagnosing malaria and a method for determining if an individual is infected with a pathogen. Provided herein is also a concentrator and a kit for use with the methods.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 19, 2022
    Assignee: ExThera Medical Corporation
    Inventors: Robert S. Ward, Keith R. McCrea
  • Patent number: 11302421
    Abstract: Methods and systems for storing digital data into peptide sequences and retrieving digital data from peptide sequences are disclosed. The method for storing digital data into peptide sequences may include: encoding the digital data into a digital code; translating the digital code into the peptide sequences; and synthesizing the translated peptide sequences. The method for retrieving digital data from peptide sequences may include: sequencing and determining an order of the peptide sequences; converting the peptide sequences with the determined order into a digital code; and decoding the digital data from the digital code. Codes with error-correction capability are developed for encoding digital data into peptide sequences, and a computational method implemented in a software is developed for sequencing the digital data bearing peptides.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: April 12, 2022
    Assignee: THE HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Zhongping Yao, Cheuk Chi Albert Ng, Haidi Yin
  • Patent number: 11299520
    Abstract: The invention features engineered probiotic lacto acid bacteria (LAB) expressing a chimeric Clostridium difficile/Lactobacillus acidophilus SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: April 12, 2022
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Gayatri Vedantam, Virinchipuram Viswanathan
  • Patent number: 11291720
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: April 5, 2022
    Assignee: AKESO BIOPHARMA, INC.
    Inventors: Baiyong Li, Yu Xia, Zhongmin Wang, Peng Zhang, Xinghua Pang
  • Patent number: 11285196
    Abstract: The presently-disclosed subject matter includes a multivalent biological construct that comprises a scaffold of anisometric dimensions, comprises a biodegradable hydrophobic core coated with a hydrophilic coat of fluidic material, and pluralities of bioactive molecules tethered to said scaffold. The multivalent biologic construct interacts simultaneously with multiple corresponding binding sites, increasing the functional affinity to induce an augmented therapeutic action in the form of stimulation, activation, competitive inhibition, consumptive inhibition or modulation of a biological system. Embodiments of the presently-disclosed subject matter include methods for preparation of the present construct as well as methods for using the present constructs to overcome cellular resistance, as thrombolytics, as competitive inhibitors, as consumptive inhibitors, as vaccines and as immunomodulators to treat a subject in need thereof.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 29, 2022
    Inventor: Eslam Abbas Baseuny
  • Patent number: 11278577
    Abstract: Engineered bacteria that secrete therapeutic polypeptides, pharmaceutical compositions comprising the bacteria, methods for producing recombinant polypeptides, and methods for using the bacteria for diagnostic and therapeutic purposes are provided.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: March 22, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Peter Q. Nguyen, Neel Satish Joshi
  • Patent number: 11259740
    Abstract: The present invention pertains to methods of determining where, on the skin, a diagnostic, therapeutic, or cosmetic agent is likely to be most effectively applied (e.g., injected), and to methods for monitoring a patient after such an agent has been administered. The monitoring can produce information useful in determining whether a diagnostic, therapeutic (e.g., surgical), or cosmetic regime should be initiated, continued, continued in a modified fashion, or terminated (e.g., for a brief or prolonged period of time). The methods can be repeated periodically and use a non-invasive, in vivo form of digital image speckle correlation (DISC) to track deformation of the skin.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 1, 2022
    Assignee: The Research Foundation for State University of New York
    Inventors: Divya Bhatnagar, Miriam Rafailovich, Raphael Davis, Alexander B. Dagum, Duc T. Bui
  • Patent number: 11252957
    Abstract: Described herein are nucleic acid-peptide capsule complexes or nanoparticles comprising pre-formed peptide capsules and nucleic acids bound the exterior surface of the capsule, such that the wrap around the capsule membrane. The peptide capsules comprise bilayer membrane defining a liquid-receiving interior space and comprises a plurality of branched, amphipathic peptides. Method of making and using such complexes for delivering nucleic acids in vivo and in vitro are also described.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: February 22, 2022
    Assignee: Kansas State University Research Foundation
    Inventors: John M. Tomich, Gerald Reeck, Luz Adriana Avila Flores, Raman Chandrasekar
  • Patent number: 11246927
    Abstract: The present invention relates to agents for use in the treatment of glioma, in particular astrocytoma WHO I? and 111°, as well as IV0 (glioblastoma), in a subject.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: February 15, 2022
    Assignee: DC EUROPA LIMITED
    Inventors: Matthias Osswald, Wolfgang Wick, Frank Winkler, Erik Jung, Jonas Blaes
  • Patent number: 11242532
    Abstract: Disclosed herein are three-dimensional cage molecules, wherein the cage molecule is composed of RNA. Also disclosed is a composition including the three-dimensional cage molecule, as well as a pharmaceutical composition containing the three-dimensional cage molecule. Also disclosed herein are methods of administering a cage molecule, composition, or formulation thereof to a subject in need thereof.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: February 8, 2022
    Assignees: Ohio State Innovation Foundation, Ball State University
    Inventors: Peixuan Guo, Daniel Jasinski, Hui Li, Emil Khisamutdinov
  • Patent number: 11241500
    Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 8, 2022
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
  • Patent number: 11229678
    Abstract: The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-arg sequence or an arginine-rich peptide.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: January 25, 2022
    Assignee: ARGENICA THERAPEUTICS PTY LTD
    Inventor: Bruno Meloni
  • Patent number: 11220476
    Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: January 11, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Kerry E. Benenato, Mark Cornebise
  • Patent number: 11215607
    Abstract: To provide a biomarker which is a metabolite included in a biological sample, and which can be collected in a noninvasive method and detected in a convenient analysis method, and which varies according to progression of pathological conditions of irritable bowel syndrome (IBS). Furthermore, such biomarkers are useful for determination of the presence or absence of morbidity of IBS, determination of severity of IBS, determination of types of IBS, determination of necessity of treatment of IBS, and confirmation of drug efficacy of an IBS therapeutic agent.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: January 4, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin Fukudo, Seishi Katsumata, Hideaki Tada, Akio Hayashi, Chie Murata
  • Patent number: 11213566
    Abstract: Provided herein is a pharmaceutical or oral care product for treating or preventing oral diseases that is prepared with proteoglycan 4 (PRG4) as an active ingredient, the preparing method thereof and the use thereof in manufacturing medicaments or oral care products for treating or preventing oral diseases and maintenance of oral health. PRG4 may have efficacy in maintaining oral health and treating or preventing oral disease. This secreted glycoprotein, which is also called lubricin and superficial zone protein, is known to protect against frictional forces, cell adhesion and protein deposition.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: January 4, 2022
    Assignee: LUBRIS LLC
    Inventors: Edward R. Truitt, III, Benjamin Sullivan, Nicholas Tennison
  • Patent number: 11207395
    Abstract: The application is directed to in vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: December 28, 2021
    Assignee: Sanaria Inc.
    Inventors: Abraham G. Eappen, Stephen L. Hoffman
  • Patent number: 11191845
    Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: December 7, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
  • Patent number: 11185501
    Abstract: Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: November 30, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Michael R. McDevitt, Simone Alidori, Nima Akhavein, David A. Scheinberg
  • Patent number: 11186868
    Abstract: The invention relates to mutant forms of CsgG. The invention also relates to analyte detection and characterisation using CsgG.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: November 30, 2021
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Lakmal Jayasinghe, Elizabeth Jayne Wallace
  • Patent number: 11185715
    Abstract: A method of image-guided radiation treatment is described. The method may include acquiring a pre-treatment image of a patient and generating a first set of image data of part or all of the patient using imaging radiation at a first energy level and a second set of image data of part or all of the patient using imaging radiation at a second energy level. The method may also include processing the first and second sets of image data to generate an enhanced image, wherein the enhanced image comprises a combination of the first and second sets of image data, and wherein part or all of the image data comprises the target. The method may also include registering the enhanced image with the pre-treatment image to obtain a registration result and tracking movement and position of the target using the registration result to generate tracking information.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: November 30, 2021
    Assignee: Accuray Incorporated
    Inventors: Petr Jordan, Andriy Myronenko, Jay B. West, Calvin R. Maurer, Prashant Chopra, Anuj K. Purwar, Christopher A. Janko
  • Patent number: 11179449
    Abstract: The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: November 23, 2021
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Université Paris-Saclay
    Inventors: Fathia Mami-Chouaib, Aurélie Durgeau
  • Patent number: 11180543
    Abstract: The invention provides methods for the treatment of neonatal hypoxia and associated white matter disease or injury, particularly in infant, including neonatal, animals, particularly Periventricular Leukomalacia (PVL) comprising administering one or more CNS reactive antibody, particularly selected from IgM12, IgM22, IgM42 and IgM46. Compositions for use in treatment of white matter disease or injury in infants, particularly PVL are provided. The invention provides methods for alleviation of neuromotor or neurodevelopmental deficits associated with neonatal hypoxia and associated with white matter injury, including PVL, in an infant.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: November 23, 2021
    Assignee: Mayo Foundation For Medical Education and Research
    Inventors: Jens O. Watzlawik, Arthur E. Warrington, Moses Rodriguez, William A. Carey
  • Patent number: 11160882
    Abstract: Indirect chromoendoscopy is performed by providing a subject with an orally administered composition which includes indigo carmine dye mixed with polyethylene glycol (PEG). Preferably, the subject ingests at least 160 mg of indigo carmine prior to the endoscopic procedure. This is accomplished by ingesting 1 ml to 6 L of a premixed or reconstituted indigo carmine and PEG composition up to twenty four hours prior to the endoscopic procedure.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: November 2, 2021
    Inventor: Toufic Kachaamy
  • Patent number: 11154620
    Abstract: Provided herein are conjugates, compositions and methods for use in photoimmunotherapy, such as photoimmunotherapy induced by activation of a phthalocyanine dye conjugated to a targeting molecule that binds a protein on cell, for example, an IR700-antibody conjugate. In some embodiments, the phthalocyanine-dye conjugate can be activated by irradiation with near-infrared light. Features of the conjugates, compositions and methods, including the dose of the conjugate, provide various advantages, such as lower toxicity and/or improved efficacy. In some embodiments, also provided is a dual label phthalocyanine-dye conjugate in which the targeting molecule is conjugated to an additional fluorescent dye, which can be used for photoimmunotherapy while, for example, also exhibiting improved performance for imaging or detection. Also provided are therapeutic methods using the conjugates and compositions for treatment of diseases and conditions, including tumors or cancers.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: October 26, 2021
    Assignee: Rakuten Medical, Inc.
    Inventors: Miguel Garcia-Guzman, Eileen Sun Chin, Deepak Yadav, Jerry Fong
  • Patent number: 11141496
    Abstract: Berberine or its derivatives are used in the preparation of myocardial perfusion imaging agents It has been verified using in vitro investigations, in vivo biodistribution, and small animal PET dynamic imaging, etc., that 18F-labeled berberine derivatives can specifically accumulate in cardiomyocytes or heart tissues, and has good distribution properties of targetting heart muscle in living animals, together with high contrast values of heart v.s. peripheral tissue (liver, lung, blood, muscle, bone, etc.).
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: October 12, 2021
    Assignee: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
    Inventors: Chengzhong Fan, Xiaoai Wu, Meng Liang, Xiaoli Mei, Tong Zhang, Rang Wang, Haotian Chen
  • Patent number: 11136396
    Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: October 5, 2021
    Assignee: MedImmune Limited
    Inventors: Thomas Linke, William K. Wang, Ambarish Shah, Hasige Sathish, Alan Hunter, Christopher Thompson
  • Patent number: 11136395
    Abstract: Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: October 5, 2021
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Hilario Ramos, Erin Willert, Richard Shimkets, Crystal Jackson, Thomas Vincent
  • Patent number: 11117935
    Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified BoNT/B4 receptor binding domain (B4-HC) having amino acid mutations that modify the binding of the BoNT to the human SytII receptor. Specific mutations and combinations of mutations are disclosed. Isolated modified HCs, polypeptides comprising such modified HCs, chimeric molecules, pharmaceutical compositions, and methods of making and using the same are also disclosed. Methods of identifying additional such modified receptor binding domains, are further disclosed.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: September 14, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Min Dong, Liang Tao
  • Patent number: 11116599
    Abstract: Imaging marker embodiments that may be used for marking sites within a patient's body are discussed. Some imaging marker embodiments are particularly useful for imaging with ultrasound imaging modalities and some imaging marker embodiments may be suitable for imaging with multiple modes of imaging modalities. Method embodiments for making and using imaging markers are also discussed herein.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: September 14, 2021
    Assignee: View Point Medical, Inc.
    Inventors: William Blair, Mike Jones, John Merritt
  • Patent number: 11110063
    Abstract: Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: September 7, 2021
    Assignee: MAIA Pharmaceuticals, Inc.
    Inventor: Srikanth Sundaram
  • Patent number: 11103567
    Abstract: Disclosed herein is a glycoconjugate vaccine conferring protection against a Gram negative pathogen infection, a method of manufacturing the glycoconjugate vaccine, and use of the glycoconjugate vaccine for treating bacterial infection. The glycoconjugate vaccine of the present disclosure has the structure of formula (I), wherein, L is a maleimide-type linker, which is connected to the carrier protein via a maleimide bond formed therebetween; and n and m are independently an integral or a non-integral number between 2 and 20.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: August 31, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Shih-Hsiung Wu, Chung-Yi Wu, I-Ming Lee, Feng-Ling Yang
  • Patent number: 11097002
    Abstract: The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 24, 2021
    Assignee: The Scripps Research Institute
    Inventors: Linling He, Jiang Zhu
  • Patent number: 11081236
    Abstract: Provided herein, inter alia, are predictive diagnostic, pharmacodynamic, and therapeutic methods for the treatment of breast cancer. In embodiments, the methods and compositions are based, at least in part, on the discovery that the estradiol (E2)-induced score or estrogen receptor (ER) pathway activity score determined from a sample (e.g., a tissue sample, e.g., a tumor tissue sample, e.g., a FFPE, a FF, an archival, a fresh, or a frozen tumor tissue sample) from an individual can be used in methods of determining whether the individual having breast cancer is likely to respond to a treatment including an endocrine therapy, selecting a therapy for an individual having breast cancer; treating an individual having breast cancer; and monitoring therapeutic efficacy of an endocrine therapy, as well as related kits.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: August 3, 2021
    Assignee: Genentech, Inc.
    Inventors: Anneleen Daemen, Ciara Metcalfe
  • Patent number: 11071759
    Abstract: The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: July 27, 2021
    Assignee: Finch Therapeutics Holdings LLC
    Inventor: Thomas J. Borody
  • Patent number: 11071729
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: July 27, 2021
    Assignees: Addex Pharmaceuticals S.A., Janssen Pharmaceuticals, Inc.
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Terry Patrick Finn